Fundamental Analysis of SAB Biotherapeutics Inc. WT - Growth / Value Index


SABSW - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.0399 indicating that it is undervalued.
   Book Value in last 3 years is trending up
   Tsr Value Index - Poor Score of 28.57
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.0186 -0.0051 92.45 %
Price to Book 0.0210 0.0024 -94.06 % 0.0044
Price to Sales 0.285 0.062 16.98 %
Enterprise Value to EBITDA Multiple 0 2.36 233.41 %


SABSW - Profitability Highlights

Profitability Analysis

   Excellent QoQ /QoQ FY EPS growth
   Piotroski F Score - Stable Value of 4.0
   Tsr Profitability Index - Very Poor Score of 5.00
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -113.16 -47.49 21.30 % -9.51
Return On Asset -73.83 -32.42 11.95 % -7.04
Net Profit Margin -1531.84 -1215.35 -1450.20 % -532.06
Operating Profit Margin -1616.31 -1208.65 -899.11 % -1205.90
EBITDA Margin -1580.02 -1034.49 -1375.45 % -1205.90


Highlights
Market Cap0
Enterprise Value0
Price/Book TTM0.0210
Outstanding Share0
Float/ Outstanding Share%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score4.00
Altman Z Score-1.85
Sloan Ratio-0.167
Peter Lynch Fair Value0


SABSW - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 1450.20%
   Steady increase in Total Assets for last 3 Years
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 90.63 % from last year
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 2602.47 K 90.63 % 209.69 %
Gross Profit 1658.06 K 90.63 % 247.73 %
EBITDA -41119.53 K 38.20 % 36.47 %
Net Profit -39865.71 K 45.20 % 78.01 %
EPS -1.35 1225.23 % NA


SABSW - Stability Highlights

Stability Analysis

   Debt to equity ratio has decreased and is lowest in last three years
   Cash ratio of 5.23
   Altman Z Score of -1.85 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -82.70
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0323 -48.18 % 0.0286
Cash Ratio 5.23 421.25 %
Quick Ratio 0 0 % 5.65
Shareholders Equity 68.26 11.88 %
Debt to EBITDA -0.080 30.82 %


Historical Valuation Ratios of SAB Biotherapeutics Inc. WT

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of SAB Biotherapeutics Inc. WT

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of SAB Biotherapeutics Inc. WT

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of SAB Biotherapeutics Inc. WT

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)